Xinbang Pharmaceutical released its 2026 interim report. First-half net profit attributable to the parent was 99.59 million yuan, down 7.1% year-on-year. Operating revenue was 2.47 billion yuan, down 13.3% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 76.64 million yuan, down 28.1% year-on-year. Net operating cash flow was 401 million yuan, up 76.5% year-on-year. Earnings per share were 0.0512 yuan. In the second quarter, operating revenue was 1.2 billion yuan, down 14.3% year-on-year. Net profit attributable to the parent was 50.93 million yuan, down 22.8% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 29.49 million yuan, down 55.0% year-on-year. As of the end of the second quarter, total assets were 8.391 billion yuan, down 2.3% from the end of the previous year. Net assets attributable to the parent were 6.751 billion yuan, down 0.6% from the end of the previous year. The company said its main business operations have not changed, and it continues to engage in medical services, pharmaceutical distribution, and pharmaceutical manufacturing, but it faces challenges from changes in the external environment and intensifying industry competition.
Guizhou Xinbang Pharmaceutical Co LtdFirst-half net profit attributable to parent fell 7.1% YoY and revenue dropped 13.3% YoY, with Q2 profit down 22.8%.
